Central India Chronicle

DelveInsight Highlights Major Advances, Transformative Therapies, and 5+ Leading Players Wheeling the Pre-Eclampsia Clinical Trial Pipeline Landscape

 Breaking News
  • No posts were found

DelveInsight Highlights Major Advances, Transformative Therapies, and 5+ Leading Players Wheeling the Pre-Eclampsia Clinical Trial Pipeline Landscape

September 19
00:55 2023
DelveInsight Highlights Major Advances, Transformative Therapies, and 5+ Leading Players Wheeling the Pre-Eclampsia Clinical Trial Pipeline Landscape

DelveInsight’s, “Pre-Eclampsia Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Pre-Eclampsia pipeline landscape. It covers the Pre-Eclampsia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Pre-Eclampsia Pipeline Report

  • DelveInsight’s Pre-Eclampsia pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Pre-Eclampsia treatment.
  • The leading companies working in the Pre-Eclampsia Market include Kyowa Kirin, Gmax Biopharm, Vicore Pharma, and others.
  • Promising Pre-Eclampsia Pipeline Therapies in the various stages of development include Antithrombin gamma, physiological saline, Anti-digoxin antibody (FAB fragment), Oxytocin, Misoprostol Oral Tablet, and others.
  • July 2023: Kyowa Kirin Co. Ltd announced a study of Phase 3 Clinical Trials for Antithrombin Gamma and Physiological Saline. The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.

 

Request a sample and discover the recent advances in Pre-Eclampsia Treatment Drugs @ Pre-Eclampsia Infection Pipeline Report

 

The Pre-Eclampsia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Pre-Eclampsia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Pre-Eclampsia clinical trial landscape.

 

Pre-Eclampsia Overview

Pre-Eclampsia is a hypertensive disease that occurs during pregnancy. The parameters for the initial identification of preeclampsia are specifically defined as a systolic blood pressure of 140 mm Hg or more or a diastolic blood pressure of 90 mm Hg or more on two occasions at least 4 hours apart; or shorter interval timing of systolic blood pressure of 160 mm Hg or more or diastolic blood pressure of 110 mm Hg or more, all of which must be identified after 20 weeks of gestation.

 

Find out more about Pre-Eclampsia Treatment Drugs @ Drugs for Pre-Eclampsia Treatment

 

Pre-Eclampsia Emerging Drugs Profile

  • KW-3357: Kyowa Kirin

 

Pre-Eclampsia Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Pre-Eclampsia. The Pre-Eclampsia companies which have their Pre-Eclampsia drug candidates in the most advanced stage, i.e. Phase III include, Kyowa Kirin.

 

Learn more about the emerging Pre-Eclampsia Pipeline Therapies @ Pre-Eclampsia Clinical Trials Assessment

 

Scope of the Pre-Eclampsia Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Pre-Eclampsia Companies- Kyowa Kirin, Gmax Biopharm, Vicore Pharma, and others.
  • Pre-Eclampsia Pipeline Therapies- Antithrombin gamma, physiological saline, Anti-digoxin antibody (FAB fragment), Oxytocin, Misoprostol Oral Tablet, and others.

 

Dive deep into rich insights for new drugs for Pre-Eclampsia treatment, Visit @ Pre-Eclampsia Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pre-Eclampsia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pre-Eclampsia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. KW-3357: Kyowa Kirin
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pre-Eclampsia Key Companies
  21. Pre-Eclampsia Key Products
  22. Pre-Eclampsia- Unmet Needs
  23. Pre-Eclampsia- Market Drivers and Barriers
  24. Pre-Eclampsia- Future Perspectives and Conclusion
  25. Pre-Eclampsia Analyst Views
  26. Pre-Eclampsia Key Companies
  27. Appendix

 

For further information on the Pre-Eclampsia pipeline therapeutics, reach out to Pre-Eclampsia Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking